This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Physical examination of the back should assess for posture and deformities. Pain elicited by palpating certain structures may be helpful in localizing the affected area. A neurologic exam is needed to assess for changes in gait, sensation and motor function. Determining if there are radicular symptoms, such as pain, numbness or weakness that radiate down limbs, is important for differentiating between central and peripheral causes of back pain. The straight leg test is a maneuver used to determine the presence of lumbosacral radiculopathy, which occurs when there is irritation in the nerve root that causes neurologic symptoms such as numbness and tingling. Non-radicular back pain is most commonly caused by injury to the spinal muscles or ligaments, degenerative spinal disease or a herniated disc. Disc herniation and foraminal stenosis are the most common causes of radiculopathy. Imaging of the spine and laboratory tests is not recommended during the acute phase. This assumes that there is no reason to expect that the patient has an underlying problem. In most cases, the pain subsides naturally after several weeks. People who seek diagnosis through imaging are typically less likely to receive a better outcome than are those who wait for the condition to resolve.
== E == E1cB elimination reaction Eder reaction Edman degradation Eglinton reaction Ehrlich–Sachs reaction Einhorn variant Einhorn–Brunner reaction Elbs persulfate oxidation Elbs reaction Electrochemical fluorination Electrocyclic reaction Electrophilic halogenation Electrophilic amination Elimination reaction Emde degradation Emmert reaction Enders SAMP/RAMP hydrazone-alkylation reaction Ene reaction Enyne metathesis Epoxidation Erlenmeyer synthesis, Azlactone synthesis Erlenmeyer–Plöchl azlactone and amino-acid synthesis Eschenmoser fragmentation Eschenmoser sulfide contraction Eschweiler–Clarke reaction Ester pyrolysis Ether cleavage Étard reaction Evans aldol Evans–Saksena reduction Evans–Tishchenko reaction
One non-blinded non-randomized study determined the effectiveness of emoxypine in 205 patients with clinical manifestations of lumbosacral radiculopathy (LSR). Patients were divided into two groups, and further were divided into subgroups depending on the presence of motor disturbances. All patients received a course of conventional medical treatment and physiotherapy; main group additionally received emoxypine. Thereafter, clinical-neurological control of long-term results of treatment in subgroups of patients was performed. The results showed that the use of emoxypine in the combined therapy of patients with LSR led to significant and persistent reduction of severity of pain syndrome and rapid recovery of function of spinal roots and peripheral nerves compared with conventional therapy. However, these studies are primary research, and the effectiveness or purported pharmaceutical efficiency of emoxypine has not yet been validated through a meta analysis or systematic review.
=== Thailand === Thailand has been severely impacted by the crisis. Thailand imports 57% of its oil from the Middle East, which requires to pass the Strait of Hormuz. The diesel fuel price has increased from 29.94 THB per litre in February, up to peak price of 50.54 THB per litre in 7 April. The government froze diesel prices at 29.94 THB per litre in the first 15 days of the crisis, and has directed people to raise their air-conditioning temperatures and reduce their outer clothing, to reduce energy consumption, and employees of all government agencies are working from home. Phipat Ratchakitprakarn, Deputy Prime Minister of Thailand and co-owner of PTG Energy (branded as PT), one of the largest oil companies in Thailand, was assigned by Anutin Charnvirakul, Prime Minister of Thailand to control and mitigate the impact of fuel crisis in Thailand. He has been criticised by Thai citizens for his failure to manage the impact, and the "Ban PT" movement has gained traction across the internet. In Pathum Thani Province, north of Bangkok, the local Provincial Administrative Organization (PAO) has terminated its 4.45 satang per litre (Equivalent to 0.445 THB) fuel dispenser tax for 3 months, in 317 stations across the province. Normally, this tax generates 4 million THB per month for the PAO. By this measure the PAO hopes to reduce fuel costs for the residents of Pathum Thani Province, especially for farmers.
Sources: en.wikipedia.org
Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized. On October 25, 2011, Eli Lilly & Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis.
This is a list of WWE pay-per-view (PPV) and livestreaming supercards, detailing all professional wrestling cards promoted by the American promotion available on traditional PPV outlets and livestreaming services, such as ESPN, Netflix, YouTube, and Peacock. Since 2022, to emphasize the availability of these events via streaming services that hold rights to WWE's content (such as ESPN in the United States), WWE began to refer to all PPV and livestreaming events as "Premium Live Events" (PLEs).
People can also develop CJD because they carry a mutation of the gene that codes for the prion protein (PRNP), located on chromosome 202p12-pter. This occurs in only 10–15% of all CJD cases. In sporadic cases, the misfolding of the prion protein is a process that is hypothesized to occur as a result of the effects of aging on cellular machinery, explaining why the disease often appears later in life. An EU study determined that "87% of cases were sporadic, 8% genetic, 5% iatrogenic and less than 1% variant." Testing for CJD has historically been problematic, due to the nonspecific nature of early symptoms and difficulty in safely obtaining brain tissue for confirmation. The diagnosis may initially be suspected in a person with rapidly progressing dementia, particularly when it is also found with the characteristic medical signs and symptoms such as involuntary muscle jerking, difficulty with coordination/balance and walking, and visual disturbances. Further testing can support the diagnosis and may include:
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.